Announcement on Outward Investment
Filed with SSE · · 17 pages · Chinese
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. on 6ix
Earlier from Shanghai Fosun Pharmaceutical (Group)
- Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
- Fosun Pharma Announces 2025Q3 Financial Results
- Fosun Pharma Announces 2025 Interim Results
- Fosun Pharma's Self-Developed Innovative Drug Luvometinib Tablets Gains Breakthrough Therapy Designation in Saudi Arabia
- Fosun Pharma's Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million
Later from Shanghai Fosun Pharmaceutical (Group)
- Announcement on Signing Cooperation and Option Agreement by Holding Subsidiary
- Announcement on Reply to Shanghai Stock Exchange's "Letter of Regulation in Outward Investment"
- Announcement on Completion of 2022 Non-public Offering Funded Projects and Closure of Special Accounts
- Announcement on Holding Subsidiary's Progress in Drug Clinical Trials
- Announcement on Progress in Participating in the Establishment of Private Equity Investment Fund
Follow Shanghai Fosun Pharmaceutical (Group) into a list and get an email when it puts out news.
Follow Shanghai Fosun Pharmaceutical (Group)